cbdMD (YCBD) FCF Margin (2016 - 2025)

cbdMD (YCBD) posted FCF Margin of 19.48% for Q4 2025, down 277.57% sequentially from 5.16% in Q3 2025, and down 1005.0% YoY from 2.15% in Q4 2024.

cbdMD (YCBD) FCF Margin (2016 - 2025) Analysis & Trends

cbdMD has reported FCF Margin for 10 years, with the latest figure at 19.48% in Q4 2025.

Quarterly FCF Margin fell 1005.0% year-over-year to 19.48% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 11.16% (down 743.0% YoY) and the FY2025 annual result came in at 8.53%, down 580.0% from the prior year.
FCF Margin retreated to 19.48% in Q4 2025 per YCBD's latest filing, from 5.16% in the prior quarter.
Over five years, FCF Margin peaked at 5.6% in Q2 2024 and troughed at 57.82% in Q4 2021.
A 5-year average of 20.72% and a median of 17.73% in 2024 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 3385 bps in 2021, down 4312 bps in 2021.
Over 5 years, FCF Margin stood at 57.82% in 2021, then soared by 38 bps to 35.92% in 2022, then jumped by 85 bps to 5.4% in 2023, then plunged by 75 bps to 9.43% in 2024, then sank by 107 bps to 19.48% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 19.48%, 5.16%, and 15.32% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Haleon	44.36 Bn	43.40 Bn	-	-
2	Teva Pharmaceutical Industries	43.77 Bn	40.12 Bn	2.15 Bn	7.41%
3	Zoetis	32.39 Bn	30.72 Bn	1.05 Bn	21.80%
4	Takeda Pharmaceutical	28.63 Bn	22.84 Bn	5.10 Bn	14.87%
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	26.25%
6	Viatris	18.94 Bn	18.06 Bn	1.46 Bn	8.76%
7	Neurocrine Biosciences	15.63 Bn	15.24 Bn	935.80 Mn	13.41%
8	Elanco Animal Health	12.00 Bn	11.47 Bn	798.00 Mn	17.84%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	cbdMD	5.37 Mn	3.26 Mn	3.04 Mn	-

Download Data